Ixekizumab for Psoriatic Arthritis: Safety, Efficacy, and Patient Selection

OBJECTIVE: Ixekizumab is a monoclonal antibody targeting IL-17A and licensed for psoriasis, psoriatic arthritis (PsA) and axial spondyloarthritis. Review objectives were to summarize: 1) ixekizumab safety in people with PsA, 2) ixekizumab efficacy from Phase III randomized controlled trials, and 3)...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, John, Puravath, Abin P, Orbai, Ana-Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691193/
https://www.ncbi.nlm.nih.gov/pubmed/34949934
http://dx.doi.org/10.2147/JIR.S229752

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691193/
https://www.ncbi.nlm.nih.gov/pubmed/34949934
http://dx.doi.org/10.2147/JIR.S229752

Ejemplares similares